MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers

Automatiqc™ by MMS cuts QC time by up to 33%

CANTON, Mich. (June 27, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today the launch of Automatiqc™ (pronounced: automatic). Automatiqc is a new cloud-based application that automatically performs quality control (QC) and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

Automatiqc has proven that it can reduce QC time by up to 33 percent, drastically reducing the amount of time needed to perform quality checks and allowing teams to meet aggressive QC deadlines.

This new application is highly customizable, enabling users to tailor the software to specific client style guides including journal requirements and other established guides. Automatiqc does not require special training and can be easily incorporated into a medical writer’s standard workflow. Automatiqc can be used for any Microsoft Word-based document type including, but not limited to:

  • Clinical Study Reports (CSRs)
  • Protocols and Investigator’s Brochures (IB)
  • Module 2 IND and NDA submission documents (M2.5, M2.7.1, M2.7.2, M2.7.3, M2.7.4, M2.7.5, and M2.7.6)
  • Module 5 Integrated Summary of Efficacy (ISE) and Integrated Summary of Safety (ISS)
  • Health Authority Responses and Response to Queries (RTQs)
  • Safety Narratives and Risk Management Plans (RMPs),
  • Publications for peer-reviewed journals and more!

“MMS is constantly searching for new, impactful ways to bring innovations, and efficiencies to the pharmaceutical industry, and I think we’ve proven that with the introduction of Automatiqc,” said Michelle Gayari, Executive Director, Global Operations, MMS. “The current focus for many is related to reducing budget and timelines – Automatiqc does both. We designed this perfectly programmed application to utilize our pharmaceutical industry intelligence to improve the QC process for everyone. QC is the final step before release of a document to regulators or the external environment and this efficiency allows us to be nimble to adapt to last-minute document changes.”

Using Automatiqc is easy, part of the workflow, and customizable.

“QC reviewers may need to check hundreds of style points per document; using Automatiqc ensures that every point in the style guide is checked, for every document, every time, consistently. Manual QC by different reviewers is prone to subjectivity and error – even with established guides,” said Kristin Chesney, Senior Operations & Quality Specialist, MMS. “Years from now, teams will wonder how deadlines were met without it.”

Now available!

This new application is currently available for use through a service relationship with MMS or licensing of the application as software-as-a-service (SaaS).

For questions on Automatiqc, or a free demo, fill out the form at www.mmsholdings.com/contact-us.

About MMS Holdings

MMS is an award-winning, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and Best Global CRO in the 2018 International Life Sciences Awards. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

###

< Back to News and Media